Briefing
Glofitamab in a response-adapted approach using interim FDG-PET and ctDNA for primary therapy of DLBCL (GRAIL)
Phase 2 feasibility trial of a ctDNA and FDG-PET interim response-adapted approach for primary therapy of diffuse large B-cell lymphoma. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting